Optimi Health Corp. (OPTH) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Optimi Health Corp. (OPTH) dropped -6.81% to $2.60, trading at 13% of its 52-week range ($2.02 – $6.4). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across AustraliaVANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH
Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to evaluate efficacy a
The capsules were manufactured at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently announced proposed
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OPTH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OPTH. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Optimi Health Corp. (OPTH) ranks #369 by composite RQD confidence (49/100, grade D) and #859 by equity capitalization ($14.9M). Within this direct 5-issuer industry benchmark cohort, OPTH leads on earnings valuation at N/A trailing P/E, while CTXR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OPTH currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OPTH
ACTIVE
Optimi Health Corp. | D | 49/100 | — | — | — | -6.81% | $14.9M | Benchmark Subject |
| CTXR Citius Pharmaceuticals Inc. | D | 49/100 | — | — | -35.0% | +4.07% | $15.5M | /ctxr-vs-opth → |
| NCEL NewcelX Ltd. | D- | 39/100 | — | — | -35.0% | -0.30% | $15.5M | /ncel-vs-opth → |
| ALLR Allarity Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -6.32% | $14.2M | /allr-vs-opth → |
| JAGX Jaguar Health Inc. | E | 31/100 | — | 67.2% | -35.0% | -2.86% | $15.9M | /jagx-vs-opth → |
Optimi Health Corp. (OPTH) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $14.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Optimi Health Corp. (NASDAQ: OPTH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $2.60 (-6.81% 1D, market cap $14.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OPTH ranks #369 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPTH carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CTXR (Citius Pharmaceuticals Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $15.5M) and NCEL (NewcelX Ltd.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $15.5M). Among the 5-stock peer group, OPTH leads on earnings multiple (N/A) while CTXR leads on capital efficiency (-35.0% ROIC).
For Optimi Health Corp. (OPTH), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #369 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
OPTH last traded at $2.60 (-6.81% on volume of 55,101 shares), positioning the stock -38.82% below its 50-day simple moving average ($4.25) and -43.48% below its 200-day simple moving average ($4.60). Across its 52-week range of $2.02 to $6.40, OPTH sits at the 13.2% percentile with a 14-day RSI of 18.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.27 to $2.93).
Why OPTH Stock dropped -6.81% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.